Groundbreaking research is paving the way for highly personalized cancer therapies, promising greater treatment precision and fewer side effects. Findings from the Cibir Research Group highlight the importance of incorporating targets associated with angiogenesis into RNA vaccine protocols.
The Cibir Angiogenesis unit’s study, detailing an RNA vaccine that targets adrenomedullin to reduce angiogenesis and tumor burden in a metastatic melanoma mouse model, is available for review.